Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Curevac N.V. (CVAC)

Curevac N.V. (CVAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 756,019
  • Shares Outstanding, K 224,338
  • Annual Sales, $ 579,120 K
  • Annual Income, $ 175,500 K
  • EBIT $ 192 M
  • EBITDA $ 213 M
  • 60-Month Beta 2.43
  • Price/Sales 1.32
  • Price/Cash Flow 4.15
  • Price/Book 1.08

Options Overview Details

View History
  • Implied Volatility 110.15% ( +1.52%)
  • Historical Volatility 68.75%
  • IV Percentile 49%
  • IV Rank 19.34%
  • IV High 534.89% on 10/23/24
  • IV Low 8.31% on 10/15/24
  • Put/Call Vol Ratio 1.24
  • Today's Volume 103
  • Volume Avg (30-Day) 426
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 9,728
  • Open Int (30-Day) 6,605

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +52.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.05 +10.67%
on 04/16/25
3.79 -10.99%
on 05/02/25
+0.10 (+3.06%)
since 04/14/25
3-Month
2.47 +36.44%
on 04/07/25
3.79 -10.99%
on 05/02/25
-0.28 (-7.67%)
since 02/14/25
52-Week
2.37 +42.19%
on 11/20/24
5.28 -36.17%
on 06/06/24
+0.27 (+8.71%)
since 05/14/24

Most Recent Stories

More News
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode

The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according...

BBC : 17.22 (-2.21%)
CVAC : 3.37 (-0.74%)
ONEQ : 75.41 (+0.75%)
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation

CVAC : 3.37 (-0.74%)
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...

CVAC : 3.37 (-0.74%)
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer

CVAC : 3.37 (-0.74%)
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form

CVAC : 3.37 (-0.74%)
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio

CVAC : 3.37 (-0.74%)
2 Small-Cap Stocks Set to Shine in a Bull Market

Small-cap growth-orientated stocks like HTCR and CVAC often outperform during bullish markets due to their sensitivity to improving economic conditions.

CVAC : 3.37 (-0.74%)
HTCR : 0.6752 (-0.07%)
IWM : 206.78 (-0.89%)
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?

Investors in CureVac N.V. CVAC need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $06.00 Call had some of the highest implied volatility...

CVAC : 3.37 (-0.74%)
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published...

BVAXF : 0.0246 (-2.38%)
BIOV.CN : 0.0300 (-14.29%)
CVAC : 3.37 (-0.74%)
VXRT : 0.4000 (-3.73%)
IBRX : 2.49 (-0.80%)
BNTX : 92.08 (-2.56%)
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM

CVAC : 3.37 (-0.74%)

Business Summary

CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.

See More

Key Turning Points

3rd Resistance Point 3.71
2nd Resistance Point 3.63
1st Resistance Point 3.50
Last Price 3.37
1st Support Level 3.30
2nd Support Level 3.22
3rd Support Level 3.09

See More

52-Week High 5.28
Fibonacci 61.8% 4.17
Fibonacci 50% 3.83
Fibonacci 38.2% 3.48
Last Price 3.37
52-Week Low 2.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar